The University of Chicago Header Logo

Adil Javed

TitleAssociate Professor
InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Adil Javed, MD, PhD has expertise in autoimmune diseases of the brain and spine, including multiple sclerosis, lupus, Sjögren's disease, and other related connective tissue diseases. He has particular clinical and research interests in neuromyelitis optica (NMO), also known as Devic's disease. In addition, he specializes in nervous system complications of infectious and post-infectious diseases.

    Dr. Javed is also a principle investigator in several multiple sclerosis trials. His translational research interests include analyzing brain pathology using new and unconventional magnetic resonance imaging (MRI) techniques.

    Collapse Biography 
    Collapse education and training
    The University of Chicago Medicine, ILFellowship
    Yale University School of Medicine, CTResidency
    Evanston Northwestern Hospital, ILInternship
    Southern Illinois University, ILM.D.
    Southern Illinois University, ILPh.D.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Dresser L, Chaar WA, Reder AT, Abuaf AF, Cipriani VP, Javed A. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718. PMID: 37086634.
      Citations:    Fields:    Translation:Humans
    2. Abuaf AF, Javed A, Bunting SR, Carroll TJ, Reder AT, Cipriani VP. Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523. PMID: 36773543.
      Citations: 1     Fields:    Translation:Humans
    3. Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Büdingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1). PMID: 36724181; PMCID: PMC9756307.
      Citations: 5     Fields:    Translation:Humans
    4. Abuaf AF, Bunting SR, Klein S, Carroll T, Carpenter-Thompson J, Javed A, Cipriani V. Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. PLoS One. 2022; 17(9):e0274778. PMID: 36137122; PMCID: PMC9499213.
      Citations: 1     Fields:    Translation:Humans
    5. Hasse A, Bertini J, Foxley S, Jeong Y, Javed A, Carroll TJ. Application of a novel T1 retrospective quantification using internal references (T1-REQUIRE) algorithm to derive quantitative T1 relaxation maps of the brain. Int J Imaging Syst Technol. 2022 Nov; 32(6):1903-1915. PMID: 36591562; PMCID: PMC9796586.
    6. Xie T, Padmanaban M, Javed A, Satzer D, Towle TE, Warnke P, Towle VL. Effect of Deep Brain Stimulation on Cerebellar Tremor Compared to Non-Cerebellar Tremor Using a Wearable Device in a Patient With Multiple Sclerosis: Case Report. Front Hum Neurosci. 2021; 15:754091. PMID: 35095448; PMCID: PMC8792598.
    7. Chaudhry F, Bulka H, Rathnam AS, Said OM, Lin J, Lorigan H, Bernitsas E, Rube J, Korzeniewski SJ, Memon AB, Levy PD, Schultz L, Javed A, Lisak R, Cerghet M. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020 Nov 15; 418:117147. PMID: 32980780; PMCID: PMC7834402.
      Citations: 47     Fields:    Translation:HumansCellsPHPublic Health
    8. Gilmore W, Lund BT, Li P, Levy AM, Kelland EE, Akbari O, Groshen S, Cen SY, Pelletier D, Weiner LP, Javed A, Dunn JE, Traboulsee AL. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2020 Jun 15; 17(1):189. PMID: 32539719; PMCID: PMC7296935.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    9. Conte WL, El Ammar F, Movahedan A, Shah HA, Nichols J, Javed A. Herpes Simplex Virus 2 Meningoencephalitis-Associated Bilateral Optic Neuritis and Radiculitis. Neuroophthalmology. 2020 Jun; 44(3):190-192. PMID: 32395172; PMCID: PMC7202427.
    10. Bernard J, Yong J, Arndt N, Carroll T, Lee SK, Reder AT, Javed A, Koskimäki F. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326. PMID: 30576361; PMCID: PMC6303064.
      Citations: 8     Fields:    Translation:Humans
    11. Conte WL, Arndt N, Cipriani VP, Dellaria A, Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019 Jan; 27:397-399. PMID: 30508784.
      Citations: 4     Fields:    Translation:Humans
    12. Vavasour IM, Tam R, Li DK, Laule C, Taylor C, Kolind SH, MacKay AL, Javed A, Traboulsee A. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2019 05; 25(6):811-818. PMID: 29663845.
      Citations: 10     Fields:    Translation:Humans
    13. Cipriani VP, Arndt N, Pytel P, Reder AT, Javed A. Effective treatment of CLIPPERS with long-term use of rituximab. Neurol Neuroimmunol Neuroinflamm. 2018 May; 5(3):e448. PMID: 29511706; PMCID: PMC5833333.
      Citations: 5     Fields:    
    14. Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, Tao JX, Warnke P, Rose S, Towle VL, Wu S. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018 03; 80:331-336. PMID: 29433947.
      Citations: 38     Fields:    Translation:Humans
    15. Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018; 13(1):e0190425. PMID: 29309416; PMCID: PMC5757948.
      Citations: 22     Fields:    Translation:HumansCells
    16. Bertsch-Gout M, Loeb R, Finch AK, Javed A, Bernard J. High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. J Neurol Sci. 2018 Jan 15; 384:61-66. PMID: 29249380.
      Citations: 4     Fields:    Translation:Humans
    17. Talmage GD, Coppes OJM, Javed A, Bernard J. Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(5):e0178338. PMID: 28542604; PMCID: PMC5436866.
      Citations:    Fields:    
    18. Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299. PMID: 28426702; PMCID: PMC5398512.
      Citations: 7     Fields:    Translation:Humans
    19. Javed A, Reder AT. Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e199. PMID: 26848488; PMCID: PMC4733148.
      Citations: 6     Fields:    
    20. Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: Clinical practice insights. Neurol Clin Pract. 2015 Apr; 5(2):132-142. PMID: 26137421; PMCID: PMC4404283.
      Citations: 48     
    21. Javed A, Khan O. Acute disseminated encephalomyelitis. Handb Clin Neurol. 2014; 123:705-17. PMID: 25015513; PMCID: PMC7151857.
      Citations: 19     Fields:    Translation:HumansAnimals
    22. Fan Y, McGowan S, Rubeiz H, Wollmann R, Javed A, Mastrianni J. Acute encephalopathy as the initial manifestation of CADASIL. Neurol Clin Pract. 2012 Dec; 2(4):359-361. PMID: 23634379; PMCID: PMC3613208.
      Citations: 4     
    23. Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11. PMID: 23008451; PMCID: PMC3586280.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    24. Romero RS, Gutierrez I, Wang E, Reder AT, Bhatti MT, Bernard JT, Javed A. Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3. PMID: 22580830.
      Citations: 6     Fields:    Translation:HumansCells
    25. Feng X, Reder NP, Yanamandala M, Hill A, Franek BS, Niewold TB, Reder AT, Javed A. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53. PMID: 22036215; PMCID: PMC3910514.
      Citations: 34     Fields:    Translation:HumansCells
    26. Mahmood NA, Silver K, Onel K, Ko M, Javed A. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol. 2011 Feb; 26(2):244-7. PMID: 21183724.
      Citations: 12     Fields:    Translation:Humans
    27. Pula JH, Javed A. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Curr Opin Ophthalmol. 2009 Nov; 20(6):476-81. PMID: 19816177.
      Citations: 1     Fields:    Translation:Humans
    28. Javed A, Balabanov R, Arnason BG, Kelly TJ, Sweiss NJ, Pytel P, Walsh R, Blair EA, Stemer A, Lazzaro M, Reder AT. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14. PMID: 18573828.
      Citations: 16     Fields:    Translation:Humans
    29. Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O, Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School . Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008 Feb; 7(2):173-83. PMID: 18207115.
      Citations: 30     Fields:    Translation:Humans
    30. Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006 Apr; 110(1):35-56. PMID: 16229894.
      Citations: 26     Fields:    Translation:Humans
    31. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci. 2001 May 15; 21(10):3572-9. PMID: 11331386; PMCID: PMC6762485.
      Citations: 43     Fields:    Translation:AnimalsCells
    32. Javed A, Kamradt MC, Van de Kar LD, Gray TS. D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience. 1999 Mar; 90(3):851-8. PMID: 10218785.
      Citations: 8     Fields:    Translation:AnimalsCells
    33. Javed A, Van de Kar LD, Gray TS. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res. 1998 Apr 27; 791(1-2):67-74. PMID: 9593827.
      Citations: 5     Fields:    Translation:Animals
    34. Javed A, Van De Kar LD, Gray TS. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions. Brain Res. 1997 Nov 07; 774(1-2):94-105. PMID: 9452197.
      Citations: 3     Fields:    Translation:Animals
    Javed's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (164)
    Co-Authors (21)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors